Abiopharma

🔍 Davis Matthew W. (Executive)

Company: Aquestive Therapeutics, Inc. (AQST)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 50,000 shares of Common Stock (Direct)
  Date: 2026-03-09 | Code: A | equity_swap_involved: false | shares_owned_after: 100,000.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 50,000 shares of Non-Qualified Stock Option (right to buy) at $4.29 per share (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2036-03-09 | equity_swap_involved: false | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
• F2: The option will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.